Objective To discuss possible mechanism of Shuyu Capsule（ 舒 郁 胶 囊） treating premenstrual syndrome with liver-Qi depression syndrome. Methods Sixty Wistar rats were randomly divided into blank group

model group

Shuyu Capsule group

the fluoxetine group and the saikoside group

12 rats in each group. Except for the blank group

contralateral limbs of rats in other group were bound to make model in estrous cycle. At the same time

the Shuyu Capsule group was given Shuyu Capsule 0. 408 g /（ kg·d）. The fluoxetine group was given fluoxetine hydrochloride capsule 2. 67 mg /（ kg·d）. The saikoside group was given extractive of saikoside 0. 72 mg /（ kg·d）.The blank group and the model group were given the isopyknic sterile water to gavage for 8 days. The researchers weighed those rats after medication. The rats were made open field test to collect the total distance. And the researchers extracted cortex tissue of parietal region of rats to detect expression of γ-aminobutyric acid transaminase（ GABA-T）

γ-aminobutyric acid transporter-1（ GAT-1） protein and mRNA. Results Compared with the blank group

weight of rats and the total distance of open field test reduced in the model group（ P < 0. 05）

but expression of GABA-T

GAT-1 protein and mRNA in the cortex of parietal region significantly increased（ P < 0. 05）. Compared with the model group

body weight and the total distance of open field test increased in the fluoxetine group and the Shuyu Capsule group（ P < 0. 05）

but expression of GABA-T

GAT-1 protein and mRNA in the cortex of parietal region significantly decreased（ P < 0. 05）. Conclusion Shuyu Capsule may play therapeutic role to premenstrual syndrome with liver-Qi depression syndrome by correcting the abnormal expression of GABA-T

GAT-1 to regulate disordered metabolism of GABA.